SG Americas Securities LLC bought a new stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) in the third quarter, HoldingsChannel reports. The fund bought 14,062 shares of the company’s stock, valued at approximately $179,000.
Other hedge funds have also modified their holdings of the company. Wellington Management Group LLP grew its position in UroGen Pharma by 49.3% in the fourth quarter. Wellington Management Group LLP now owns 104,600 shares of the company’s stock valued at $1,569,000 after acquiring an additional 34,537 shares in the last quarter. Oak Ridge Investments LLC purchased a new position in shares of UroGen Pharma in the first quarter valued at $918,000. BNP Paribas Financial Markets grew its holdings in UroGen Pharma by 73.1% during the 1st quarter. BNP Paribas Financial Markets now owns 39,795 shares of the company’s stock valued at $597,000 after purchasing an additional 16,799 shares in the last quarter. Vanguard Group Inc. increased its stake in UroGen Pharma by 14.3% during the 1st quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock worth $2,924,000 after buying an additional 24,367 shares during the period. Finally, Price T Rowe Associates Inc. MD purchased a new position in UroGen Pharma in the 1st quarter valued at about $4,008,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
URGN has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Oppenheimer restated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Finally, Guggenheim assumed coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $48.38.
UroGen Pharma Trading Down 2.7 %
NASDAQ URGN opened at $12.13 on Thursday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15. UroGen Pharma Ltd. has a one year low of $10.60 and a one year high of $20.70. The company has a 50-day simple moving average of $13.30 and a 200-day simple moving average of $14.32. The firm has a market capitalization of $284.45 million, a PE ratio of -3.70 and a beta of 1.11.
UroGen Pharma (NASDAQ:URGN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The company had revenue of $21.85 million during the quarter, compared to analyst estimates of $23.69 million. On average, equities analysts forecast that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
- Five stocks we like better than UroGen Pharma
- Want to Profit on the Downtrend? Downtrends, Explained.
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Stock Sentiment Analysis: How it Works
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Most Volatile Stocks, What Investors Need to Know
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UroGen Pharma Ltd. (NASDAQ:URGN – Free Report).
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.